Personalised transcranial magnetic stimulation: does brain imaging improve outcomes for people with depression or PTSD?

DennySo this crossed my desk earlier: Personalised transcranial magnetic stimulation: does brain imaging improve outcomes for people with depression or PTSD. What's your first instinct on it?

FarrahMy first thought isn't about the scan at all, it’s about the queue. A depressed patient sitting in a waiting room hoping a MRI will finally tell them why they feel stuck doesn’t get a miracle, they get another six months of uncertainty while the techs figure out how to aim the coil better. We’re talking about two tiny trials here, so calling this a breakthrough is like celebrating because the pilot light flickered once.

DennyBut wait, you’re ignoring the piece where they actually matched the stimulation to individual brain activity patterns rather than using a one-size-fits-all template. That feels less like guessing and more like finding the right key for each lock, which is exactly the kind of shift that could change whether the treatment lands at all.

FarrahFinding the right key sounds great until you realize those two trials didn’t even agree on which brain region mattered most. You can’t build a whole clinic around a hunch when the data hasn’t settled down yet.

DennyPicture a partner whose anxiety spikes every time their spouse comes home late; if the TMS hit a random spot, they’d still dread that evening commute, but hitting the specific neural circuit tied to attachment security might actually let them relax without rehearsing the worst-case scenario. That distinction between a general sedative effect and a targeted behavioral unlock is where the real value lives.

FarrahPicture someone who gets TMS aimed at a "sadness center" based on a single scan, only to find out three weeks later that their specific trauma response lights up a completely different corner of the brain. The targeting looks precise on paper, but if the underlying biology shifts week to week, that initial map becomes useless almost as soon as we print it.

DennyBut the trial design itself matters more than the biological drift. They tracked response across multiple sessions, so the targeting likely adjusted mid-treatment rather than relying on that first static map.

FarrahTracking response across multiple sessions does suggest the protocol wasn’t locked into that first snapshot, which gives some weight to your point about dynamic adjustment. However, neither of these two trials reported how many times they actually rescanned versus how often they just tweaked the coil position manually. Without knowing if fresh imaging drove those changes or if therapists were simply reacting to symptom reports, we can’t confirm the technology did what you think it did.

DennyIt is fair to say we don't know if the rescans actually changed the targets, since the trials left that gap wide open. Even assuming the therapists were just moving the coil by hand based on mood checks, the fact that symptoms improved at all proves the basic mechanism works, leaving the precision upgrade as a bonus layer rather than the foundation.

FarrahCalling manual coil adjustments proof of the mechanism is like saying a car works because the steering wheel turns when you push on it. The improvement tells us something moved, but it says nothing about whether the personalized targeting added actual clinical value beyond standard care.

DennyThink about the cost side of this equation. If a patient spends forty minutes getting scanned just to save ten minutes of ineffective treatment, that extra hour adds up quickly in a busy clinic. The real test isn't whether the target is perfect, but whether the time spent mapping brains pays off in fewer repeat visits and lower long-term costs.

FarrahForty minutes is just one unknown variable among several missing ones. We need outcome data before calculating break-even points.

DennyYou’re right that we lack hard numbers on the final tally, but looking at the logistics, scanning acts as a filter for who needs intensive follow-up versus who’s ready to taper off. If the image helps a clinician confidently end a course after six sessions instead of dragging it out to twelve, that saved time dwarfs the forty-minute investment. The real metric isn’t immediate relief, it’s preventing the relapse loop that keeps people stuck in therapy indefinitely.

FarrahEnding a course early sounds efficient until you realize we have no data showing the scan predicted that readiness better than a simple symptom checklist. Saving six weeks might look great on a spreadsheet, but without proof the imaging caught a nuance a human observer missed, we are just paying premium prices for the same guesswork.

DennyThe comparison against a baseline checklist hasn't been run yet. But stepping back, the core finding still holds: adding individual brain maps produced better outcomes than the generic approach, regardless of exactly where the gain came from. For now, treat the precision as unproven, but the direction of travel—personalized beats standard—isn't going away.

FarrahConceding that generic protocols underperform doesn't validate the expensive fix, especially when the two small trials haven't proven the imaging itself caused the difference. Until larger studies isolate the scan's specific contribution from general attention effects, we're guessing that higher precision equals better recovery. Let's wait for the bigger picture before calling this routine care.

DennyI’m not asking you to trust the scanner over your gut, just to admit that ignoring the map entirely leaves patients exposed to trial-and-error pain. Until those larger trials prove the imaging is redundant, treating it as useless ignores the risk of stopping care too late. So let’s stop debating if personalization matters in principle, and focus on whether the current scan can actually catch the relapse before it happens.